Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.42 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | RPS6KB2 | Q9UBS0 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1519103 | 0.88 | CA2 (0.49) | L3MBTL1MAPK1HPGDHTTCA2 | |
| SCHEMBL7216006 | 0.88 | L3MBTL1 (0.45) | L3MBTL1MAPK1HPGDTSHRCA2 | |
| SCHEMBL27033027 | 0.81 | CYSLTR2 (0.42) | CYSLTR2CYSLTR1HPGDHTTRPS6KB2 | |
| SCHEMBL1519389 | 0.80 | L3MBTL1 (0.48) | L3MBTL1MAPK1HPGDTSHRKDM4E | |
| SCHEMBL1519185 | 0.78 | SMN1; SMN2 (0.48) | L3MBTL1HPGDTSHRHTTCYP2C19 | |
| SCHEMBL29437007 | 0.76 | HPGD (0.61) | L3MBTL1HPGDHTTKDM4ECYP2C19 | |
| SCHEMBL229498 | 0.76 | HPGD (0.61) | L3MBTL1HPGDHTTKDM4ECYP2C19 | |
| SCHEMBL566636 | 0.76 | HPGD (0.61) | L3MBTL1HPGDHTTKDM4ECYP2C19 | |
| SCHEMBL1300333 | 0.76 | HPGD (0.61) | L3MBTL1HPGDHTTKDM4ECYP2C19 | |
| SCHEMBL7216342 | 0.75 | CA2 (0.52) | L3MBTL1MAPK1CA2KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110052562-A1 | BENZIMIDAZOLES AND ANALOGS AS RHO KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-03-03 | — | — | US | disclosed |
| US-20110052562-A1 | BENZIMIDAZOLES AND ANALOGS AS RHO KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-03-03 | — | — | US | disclosed |
| US-20110052562-A1 | BENZIMIDAZOLES AND ANALOGS AS RHO KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110052562-A1 | BENZIMIDAZOLES AND ANALOGS AS RHO KINASE INHIBITORS | ROCK1, ROCK2, ARHGDIB | L3MBTL1 2758/4885MAPK1 79/4885CYSLTR2 2359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.